Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 November 2017Website:
http://www.apellis.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:41:48 GMTDividend
Analysts recommendations
Institutional Ownership
APLS Latest News
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Meredith Kaya - Senior Vice President of Investor Relations and Strategic Finance Cedric Francois - Co-Founder and Chief Executive Officer Adam Townsend - Chief Operating Officer Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Nicholas Econom - Raymond James Phil Nadeau - TD Cowen Katherine Wang - Jefferies Ellie Merle - UBS Annabel Samimy - Stifel Douglas Tsao - H.C. Wainwright Lachlan Hanbury-Brown - William Blair Derek Archila - Wells Fargo Biren Amin - Piper Sandler Lisa Walter - RBC Greg Harrison - Scotiabank Graig Suvannavejh - Mizuho Securities Laura Chico - Wedbush Securities Operator Good morning, ladies and gentlemen.
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.
WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American Society of Nephrology (ASN) Kidney Week. The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, debilitating kidney diseases.
William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. APLS and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two therapies: Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration.
24/7 Wall St. Insights Here are some candidates to be the best-performing growth stock over the next five years.
Apellis Pharmaceuticals' Syfovre, despite initial safety concerns, shows strong revenue growth and is nearing profitability, making it a high-risk, high-reward investment. Syfovre's adjusted safety profile and bimonthly dosing offer advantages over Astellas' Izervay, though continued vigilance for retinal vasculitis is necessary. The Company's financial health is solid, with sufficient cash and assets to cover liabilities and fund operations until positive cash flow is achieved.
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) breached their fiduciary duties to shareholders.
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its June 2024 negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
What type of business is Apellis Pharmaceuticals?
Reata Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 2002. Based in the city of Plano, Texas, the company is involved in the development of new treatment methods based on the use of low molecular weight therapeutic agents with new mechanisms of action for the treatment of severe, life-threatening diseases. The main products of the company are bardoxolone methyl (a drug for the treatment of rare forms of chronic kidney disease (CKD)) and omaveloxolone (a drug for the treatment of rare neurological diseases). Both bardoxolone and omaveloxolone normalize mitochondrial function, restore redox balance, and eliminate inflammation. Since mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, bardoxolone and omaveloxolone have a variety of potential clinical applications.
What sector is Apellis Pharmaceuticals in?
Apellis Pharmaceuticals is in the Healthcare sector
What industry is Apellis Pharmaceuticals in?
Apellis Pharmaceuticals is in the Biotechnology industry
What country is Apellis Pharmaceuticals from?
Apellis Pharmaceuticals is headquartered in United States
When did Apellis Pharmaceuticals go public?
Apellis Pharmaceuticals initial public offering (IPO) was on 09 November 2017
What is Apellis Pharmaceuticals website?
https://www.apellis.com
Is Apellis Pharmaceuticals in the S&P 500?
No, Apellis Pharmaceuticals is not included in the S&P 500 index
Is Apellis Pharmaceuticals in the NASDAQ 100?
No, Apellis Pharmaceuticals is not included in the NASDAQ 100 index
Is Apellis Pharmaceuticals in the Dow Jones?
No, Apellis Pharmaceuticals is not included in the Dow Jones index
When was Apellis Pharmaceuticals the previous earnings report?
No data
When does Apellis Pharmaceuticals earnings report?
The next expected earnings date for Apellis Pharmaceuticals is 27 February 2025